Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor (Q34634156)

3 August 2017

title

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor (English)

1 reference

3 August 2017

Harry W Lampiris

1

1 reference

3 August 2017

publication date

1 January 2012

1 reference

Expert Review of Anti-infective Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

10

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

13-20

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Raltegravir: the first HIV type 1 integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Resistance to integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Resistance to HIV-1 integrase inhibitors: A structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

HIV-1 integrase inhibitor resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Retroviral intasome assembly and inhibition of DNA strand transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.157

21 January 2018

Identifiers

DOI

10.1586/ERI.11.157

1 reference

3 August 2017

1 reference